| Dennis J Lang, DO | |
|
115 N Sumter St, Suite 410, Sumter, SC 29150-4972 | |
| (803) 883-5171 | |
| (803) 305-1814 |
| Full Name | Dennis J Lang |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 22 Years |
| Location | 115 N Sumter St, Sumter, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730307463 | NPI | - | NPPES |
| 011640 | Medicaid | SC | |
| P01232420 | Other | SC | RAILROAD MEDICARE |
| 0655422 | Other | SC | CIGNA |
| 30150986 | Other | SC | SELECT HEALTH |
| 266003 | Other | SC | MEDCOST |
| AA30048552 | Other | SC | MEDICARE PTAN |
| 929530 | Other | SC | WELLCARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 1164 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mcleod Health Clarendon | Manning, SC | Hospital |
| Prisma Heath Tuomey Hospital | Sumter, SC | Hospital |
| Mcleod Regional Medical Center-pee Dee | Florence, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Prisma Health Tuomey | 2163728528 | 12 |
| Mcleod Physician Associates Ii | 8224031307 | 520 |
News Archive
Women with hereditary breast cancer treated with breast conserving therapy appear to have no increased risk for recurrence in the treated breast, according to results from a prospective study published in the January 1, 2005 issue of CANCER, a peer-reviewed journal of the American Cancer Society.
Over the last twelve months, the NHS has been fundamentally reshaped. Plans and ideas that were bubbling away in the background for years suddenly received the green light by default. 2020 saw a huge increase in the adoption of digital technologies within modern healthcare economies.
Ambit Biosciences, today announced that it has initiated separate Phase I trials for two products AC430, a selective Janus Kinase 2 (JAK2) inhibitor, and AC480, a pan-HER inhibitor.
A study that looked at how people behave during pandemics has identified key demographic and psychological factors that may predict protective behaviours. The study is published online today, 30th January 2010, in the British Journal of Health Psychology.
Merrion Pharmaceuticals Plc, a publicly listed product development company, today announced the commencement of an oral drug delivery Feasibility and Option agreement with one of the world's top ten biggest pharmaceutical companies. The agreement will evaluate the ability of Merrion's patented GIPET technology to boost the bioavailablity of three of the 'big pharma' company's compounds.
› Verified 4 days ago
| Entity Name | Mcleod Physician Associates Ii |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801990494 PECOS PAC ID: 8224031307 Enrollment ID: O20060926000568 |
News Archive
Women with hereditary breast cancer treated with breast conserving therapy appear to have no increased risk for recurrence in the treated breast, according to results from a prospective study published in the January 1, 2005 issue of CANCER, a peer-reviewed journal of the American Cancer Society.
Over the last twelve months, the NHS has been fundamentally reshaped. Plans and ideas that were bubbling away in the background for years suddenly received the green light by default. 2020 saw a huge increase in the adoption of digital technologies within modern healthcare economies.
Ambit Biosciences, today announced that it has initiated separate Phase I trials for two products AC430, a selective Janus Kinase 2 (JAK2) inhibitor, and AC480, a pan-HER inhibitor.
A study that looked at how people behave during pandemics has identified key demographic and psychological factors that may predict protective behaviours. The study is published online today, 30th January 2010, in the British Journal of Health Psychology.
Merrion Pharmaceuticals Plc, a publicly listed product development company, today announced the commencement of an oral drug delivery Feasibility and Option agreement with one of the world's top ten biggest pharmaceutical companies. The agreement will evaluate the ability of Merrion's patented GIPET technology to boost the bioavailablity of three of the 'big pharma' company's compounds.
› Verified 4 days ago
| Entity Name | Prisma Health Tuomey |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548625593 PECOS PAC ID: 2163728528 Enrollment ID: O20160310001016 |
News Archive
Women with hereditary breast cancer treated with breast conserving therapy appear to have no increased risk for recurrence in the treated breast, according to results from a prospective study published in the January 1, 2005 issue of CANCER, a peer-reviewed journal of the American Cancer Society.
Over the last twelve months, the NHS has been fundamentally reshaped. Plans and ideas that were bubbling away in the background for years suddenly received the green light by default. 2020 saw a huge increase in the adoption of digital technologies within modern healthcare economies.
Ambit Biosciences, today announced that it has initiated separate Phase I trials for two products AC430, a selective Janus Kinase 2 (JAK2) inhibitor, and AC480, a pan-HER inhibitor.
A study that looked at how people behave during pandemics has identified key demographic and psychological factors that may predict protective behaviours. The study is published online today, 30th January 2010, in the British Journal of Health Psychology.
Merrion Pharmaceuticals Plc, a publicly listed product development company, today announced the commencement of an oral drug delivery Feasibility and Option agreement with one of the world's top ten biggest pharmaceutical companies. The agreement will evaluate the ability of Merrion's patented GIPET technology to boost the bioavailablity of three of the 'big pharma' company's compounds.
› Verified 4 days ago
| Entity Name | Mcleod Health Clarendon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508218793 PECOS PAC ID: 0840582656 Enrollment ID: O20160915000930 |
News Archive
Women with hereditary breast cancer treated with breast conserving therapy appear to have no increased risk for recurrence in the treated breast, according to results from a prospective study published in the January 1, 2005 issue of CANCER, a peer-reviewed journal of the American Cancer Society.
Over the last twelve months, the NHS has been fundamentally reshaped. Plans and ideas that were bubbling away in the background for years suddenly received the green light by default. 2020 saw a huge increase in the adoption of digital technologies within modern healthcare economies.
Ambit Biosciences, today announced that it has initiated separate Phase I trials for two products AC430, a selective Janus Kinase 2 (JAK2) inhibitor, and AC480, a pan-HER inhibitor.
A study that looked at how people behave during pandemics has identified key demographic and psychological factors that may predict protective behaviours. The study is published online today, 30th January 2010, in the British Journal of Health Psychology.
Merrion Pharmaceuticals Plc, a publicly listed product development company, today announced the commencement of an oral drug delivery Feasibility and Option agreement with one of the world's top ten biggest pharmaceutical companies. The agreement will evaluate the ability of Merrion's patented GIPET technology to boost the bioavailablity of three of the 'big pharma' company's compounds.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dennis J Lang, DO Po Box 3239, Florence, SC 29502-3239 Ph: (843) 777-7162 | Dennis J Lang, DO 115 N Sumter St, Suite 410, Sumter, SC 29150-4972 Ph: (803) 883-5171 |
News Archive
Women with hereditary breast cancer treated with breast conserving therapy appear to have no increased risk for recurrence in the treated breast, according to results from a prospective study published in the January 1, 2005 issue of CANCER, a peer-reviewed journal of the American Cancer Society.
Over the last twelve months, the NHS has been fundamentally reshaped. Plans and ideas that were bubbling away in the background for years suddenly received the green light by default. 2020 saw a huge increase in the adoption of digital technologies within modern healthcare economies.
Ambit Biosciences, today announced that it has initiated separate Phase I trials for two products AC430, a selective Janus Kinase 2 (JAK2) inhibitor, and AC480, a pan-HER inhibitor.
A study that looked at how people behave during pandemics has identified key demographic and psychological factors that may predict protective behaviours. The study is published online today, 30th January 2010, in the British Journal of Health Psychology.
Merrion Pharmaceuticals Plc, a publicly listed product development company, today announced the commencement of an oral drug delivery Feasibility and Option agreement with one of the world's top ten biggest pharmaceutical companies. The agreement will evaluate the ability of Merrion's patented GIPET technology to boost the bioavailablity of three of the 'big pharma' company's compounds.
› Verified 4 days ago
Fritz E Jean Gilles, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 129 N Washington St, Sumter, SC 29150 Phone: 803-774-9680 Fax: 803-774-5217 | |
Dr. Thomas E Hawkey, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 12 Barnette Dr, Sumter, SC 29150 Phone: 803-773-5442 Fax: 803-778-2394 | |
Dr. Joseph Cecil Williams, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 129 N Washington St, Sumter, SC 29150 Phone: 803-774-1788 Fax: 803-774-9113 | |
Dr. John Julian Abbott, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 129 N Washington St, Sumter, SC 29150 Phone: 803-774-5248 | |
Dr. Theophilus D Williams Iii, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 641 W Wesmark Blvd, Sumter, SC 29150 Phone: 803-905-6944 Fax: 803-469-3944 | |
Harry A Jordan, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1295 Wilson Hall Rd, Sumter, SC 29150 Phone: 803-905-6800 Fax: 803-905-6810 | |
Dr. Floyd L Angus, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 641 W Wesmark Blvd, Sumter, SC 29150 Phone: 803-905-6944 Fax: 803-469-3944 |